15 Most Promising Mid-Cap Healthcare Stocks Under $50

Page 2 of 15

14. AtriCure (NASDAQ:ATRC)

Sector/Industry: Healthcare (Medical Instruments & Supplies)

Share Price: $40.95

Potential Upside: 26.6%

Number of Hedge Fund Holders: 23

AtriCure (NASDAQ:ATRC) is one of the most promising mid-cap healthcare stocks under $50.

On December 16, J.P. Morgan analyst Lilia-Celine (Lily) reiterated her bullish stance on AtriCure (NASDAQ:ATRC). The analyst assigned a Buy rating and raised her price target on the stock from $42 to $48 per share. According to Lily’s estimates, the stock offers an upside potential of over 17% for investors.

AtriCure (NASDAQ:ATRC) recently announced the successful completion of its first-in-human atrial procedures combining the emerging Pulsed Field Ablation (PFA) technology with its Radiofrequency Ablation (RFA) franchise. These procedures were performed at Victoria Heart Hospital in Australia and are intended to electrically isolate key regions during complex atrial procedures.

The company President and CEO, Michael Carre,l said:

“Our innovative EnCompass clamp technology was a significant step in streamlining cardiac surgery ablation procedures. Now, building on the proven performance of our EnCompass clamp, this platform offers the best of both worlds. By pairing advanced RFA with PFA, we’re delivering unprecedented speed and flexibility for surgeons.”

As of December 19, consensus sentiment on AtriCure (NASDAQ:ATRC) remains bullish. The company has received Buy ratings from all six analysts providing coverage. Based on estimates, the stock’s 1-year median price target is $51.83, implying an impressive 26.6% upside.

AtriCure (NASDAQ:ATRC) is a medical device company offering innovative technologies for Atrial Fibrillation (Afib) for cardiac patients. They provide solutions for surgical ablation of cardiac tissues, management of left atrial appendage (LAA), and other surgical tools for thoracic procedures.

Page 2 of 15